Co-Authors
This is a "connection" page, showing publications co-authored by DEMETRIOS PETROPOULOS and PARTOW KEBRIAEI.
Connection Strength
0.678
-
Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies. Front Immunol. 2022; 13:1032397.
Score: 0.220
-
Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant. BMC Cancer. 2023 Dec 20; 23(1):1258.
Score: 0.059
-
Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant. Res Sq. 2023 Feb 07.
Score: 0.056
-
Author Correction: Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol. 2021 Jul; 18(7):468.
Score: 0.050
-
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol. 2021 07; 18(7):435-453.
Score: 0.049
-
Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. Front Oncol. 2021; 11:625707.
Score: 0.049
-
Haploidentical transplants for patients with relapse after the first allograft. Am J Hematol. 2020 Oct; 95(10):1187-1192.
Score: 0.047
-
Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy. Clin Case Rep. 2020 Sep; 8(9):1678-1681.
Score: 0.046
-
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 2019 01; 16(1):45-63.
Score: 0.042
-
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016 Nov 15; 122(21):3316-3326.
Score: 0.035
-
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leuk Lymphoma. 2012 May; 53(5):901-6.
Score: 0.026